Abbott Laboratories (ABT) Share-based Compensation (2009 - 2026)

Abbott Laboratories has reported Share-based Compensation for 18 years, with the latest figure at $168.0 million in Q2 2026.

• Quarterly Share-based Compensation rose 18.31% year-over-year to $168.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $718.0 million (up 8.95% YoY) and the FY2025 annual result came in at $664.0 million, down 1.34% from the prior year.
• Share-based Compensation eased to $168.0 million in Q2 2026 per ABT's latest filing, from $317.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $317.0 million in Q1 2026 and troughed at $111.0 million in Q4 2024.
• A 5-year average of $175.1 million and a median of $136.5 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation plunged 77.98% in 2022, then climbed 18.31% in 2026.
• Over 5 years, Share-based Compensation stood at $115.0 million in 2022, then declined by 0.87% to $114.0 million in 2023, then fell by 2.63% to $111.0 million in 2024, then increased by 1.8% to $113.0 million in 2025, then jumped by 48.67% to $168.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $168.0 million, $317.0 million, and $113.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.